Table 3.
Linear regression analyses of the correlation between hsCRP and disease activity of SLE
| SLEDAI score | Slope (SE) | Beta | *Adjusted P |
|---|---|---|---|
| Renal | 0.55 (0.29) | 0.12 | 0.06 |
| Hematological | 5.98 (1.88) | 0.19 | 0.002 |
| Musculoskeletal | 2.25 (0.64) | 0.21 | 0.001 |
| Dermatological | 1.24 (0.78) | 0.10 | 0.11 |
| Neuropsychiatric | −0.66 (1.12) | −0.04 | 0.56 |
| Serositis | 11.6 (1.33) | 0.46 | <0.001 |
| Cutaneous vasculitis | 0.44 (0.57) | 0.05 | 0.44 |
| Serology | 1.10 (0.48) | 0.14 | 0.02 |
| Total SLEDAI | 0.57 (0.14) | 0.25 | <0.001 |
| **Clinical SLEDAI | 0.64 (0.17) | 0.24 | <0.001 |
| PGA score | 5.40 (1.01) | 0.32 | <0.001 |
| Anti-dsDNA titer | 0.03 (0.005) | 0.33 | <0.001 |
| Complement C3 level | −3.46 (3.06) | −0.07 | 0.26 |
Beta is the regression coefficient in the linear regression models
*
adjusted for age, sex, serum creatinine, body mass index and the use of medications (prednisolone, hydroxychloroquine, mycophenolate mofetil, azathioprine, calcineurin inhibitors, statins and angiotensin converting enzyme inhibitors)
**
Clinical SLEDAI score = total SLEDAI score minus SLEDAI score due to elevated anti-dsDNA or depressed complements
SLEDAI = systemic lupus erythematosus disease activity index; PGA = physician’s global assessment